DNAP Research and Product
Development ? Milestones For Forensics and Consumer
Markets
ANCESTRYbyDNA 2.0(TM)
R/D 2000-01?
4Q 2002 market? Mar2004*replaced w/ V2.5
ANCESTRYbyDNA
2.5(TM)
R/D 2003????.Feb2004
market
ANCESTRYbyDNA 3.0(TM)
R/D 2005???2006
market?
EURO-DNA(TM) 1.0
R/D 2003???.......4Q 2004
market
DNAWitness(TM) 2.0
R/D 2002?????.2003
market??...2004*replaced w/ V2.5
DNAWitness(TM) 2.5
?R/D 2003...July 2004 market?Test kit - late 2005 ...global
sales 2006
DNAWitness(TM)
3.0????????????...............R/D 2005 (3.0 to include eye
color)
EURO Witness(TM) 1.0????????????R/D
2004????.Feb2005 market
RETINOME(TM) 1.0 Eyecolor.
?R/D 2003....4Q 2004 market?Test kit - late 2005?global sales
2006
RETINOME HA[(TM) Haircolor??.R/D 2004?.2005-06
validate?..2007 beta test??..2008 market?
SKIN
SHADE?????????????.R/D 2005????...R/D 2006-07??2008
market?
Genetic Family Tree DB????.????????????R/D
2004????.online 2005
Searchable Ancestry Genealogy
DB????...R/D 2003??.online 2004???.expand
2005
Searchable PhotoAncestryDB (Forensics)??R/D
2003??..online 2004???..expand 2005
DNA Database for
Native Americans?develop 2003/2004?.expand 2005
DNA
Database for African-Americans?.develop 2005
DNAP
Research and Product Development ? Milestones For Pharmacogenomics
and Theranostics
DNAP? Drug Research Projects:
1)
Ovanome - Taxol/Carboplatin efficacy
* R/D 1998.?Announce
Mar 2000?Validation Studies 2002-2004?.Clinical Study May 2005?FDA
IND late 2006?.
2) Statinome - Lipitor, Zocor,
efficacy, liver, muscle adverse myalgia response
* R/D
1998?.Clinical Studies late 2004/early 2005?FDA IND
2007?...Market?...
3) Acenome - Enalapril, Lisinopril
efficacy, muscle, adverse cough
* R/D 1998?.Clinical Studies
late 2004/early 2005?FDA IND 2007?...Market?...
4)
Immunosuppressants - Sirolimus, Tacrolimus,
Mycophenolate
* R/D 2001?NYU Open R/D??.
5) Super EPO
Anemia Drug
* License Apr 2005?Pre-clinical 4thQ
2005/2006?FDA IND late 2006/early 2007?.
* DNAP exclusive
worldwide license to develop a Super EPO drug with a $10 billion
dollar market potential.
6) Acute Lymphocyte Leukemia
(ALL)
* R/D 2005?Joint Publication late 2005?.DNA Screening
Test 2006??..
7) Cervical Cancer and ETS
* FAMRI
Grant Feb 2003?.2 year grant?.Publication 2006?....
DNAP and
Moffitt Cancer Center ? Drug Research Projects:
Cancer
research partnership announced March 2004?R/D ongoing for over one
year?
1) Response of Metastatic Colorectal Cancer to
Irinotecan/Capecitabine (Xeliri) and Oxaliplatin/Capecitabine
(Xelox)
2) Melphalan and Topotecan (MT) efficacy for
treatment of Multiple Myeloma
3) Cyclophosphamide
efficacy
4) Organistron adverse events - post operative
nausea and vomiting
5) Esophageal malignancy chemotherapy
response - standard FDA treatment
Note: All above data on
DNAP's research and drug product pipeline are from DNAP newsletters,
PR's and SEC filings.
Projects listed may or may not be
inclusive of all possible projects DNAP may be involved in. Please
feel free to add or update.
* JMHO ? The above numerous
unique forensics and consumer products and cancer research projects,
and especially our new Super EPO anemia drug, are more ?tools? by
far than most all other biotech?s have put together. Not listed
above are DNAP?s pending patents, journal articles, publications,
actively working with many US law enforcement agencies, the FBI, New
Scotland Yard, Australia and others. They have successfully helped
in numerous cases and are currently involved with at least 80
others, getting DNA Witness test kits ready for mass production and
global sales for the forensics markets.
And the most exciting
recent MAJOR accomplishment by DNAP?s management team is that they
put DNAPrint Genomics solidly on the drug development path with our
own drug.
This management team has recently licensed a Super
EPO anemia drug with a $10 billion dollar market potential with
Harvard?s affiliate, Beth Israel, and turned DNAPrint Genomics into
a new small drug company?.this accomplishment alone is brilliant and
worth investors support for management. It definitely has
mine?
DNAP has a heck of a lot more going for it than the
normal small company doing an R/S to survive. Management has
accomplished much in under 2 years and has earned my continued
support to take us the next step....DNAP as a successful small drug
company.
It will be a combination of many of the above and/or
some new blockbuster stuff going on behind the scenes that will keep
us on track after any R/S...
Of course...do your own DD and
make your own decisions...but for a lowly penny, I'm in for the ride
and I'm betting on the potential.
God?s Speed To DNAP and To
All DNAP
Investors,
Robert
|
This Site is Not Owned by DNAPrint
Sarasota Florida
